Today: 29 June 2026
Browse Category

NYSE:TMO 31 July 2025 - 4 December 2025

Thermo Fisher Scientific (TMO) Stock on December 2, 2025: Price Action, HSBC Upgrade, New Debt Deal and 2026–2030 Forecasts

Thermo Fisher Scientific (TMO) Stock on December 2, 2025: Price Action, HSBC Upgrade, New Debt Deal and 2026–2030 Forecasts

Thermo Fisher Scientific shares traded near $580 midday Tuesday, down less than 1% but close to their 52-week high of $611. HSBC raised its price target on the stock to $670. The company recently announced a €2.1 billion bond sale and a $5 billion share repurchase plan. An insider filed to sell 6,912 shares valued at about $4 million.
2 December 2025
··
Thermo Fisher Scientific (TMO) Stock on 1 December 2025: HSBC Upgrade, Insider Moves, Buyback and 2026–2030 Forecasts

Thermo Fisher Scientific (TMO) Stock on 1 December 2025: HSBC Upgrade, Insider Moves, Buyback and 2026–2030 Forecasts

Thermo Fisher Scientific shares traded at $584–585 on December 1, 2025, with a market cap near $223 billion and a P/E ratio of 34.2. HSBC upgraded the stock to “Buy” the same day, citing improved prospects. Boston Family Office increased its stake by 3% in Q2, while First National Advisers cut its position by 59%. Institutional investors hold about 89% of the float.
1 December 2025
··
Thermo Fisher Scientific (TMO) Stock News Today: Insider Selling, Institutional Buying and New Growth Moves – November 28, 2025

Thermo Fisher Scientific (TMO) Stock News Today: Insider Selling, Institutional Buying and New Growth Moves – November 28, 2025

Thermo Fisher Scientific traded near $590.83 per share late Friday, with a market cap of about $222 billion. Institutional investors, including Global Retirement Partners and Laurel Wealth Advisors, disclosed new or increased stakes. An executive vice president sold $6.43 million in shares. The stock remains near its 52-week high of just over $610.
29 November 2025
·
Thermo Fisher (TMO) Stock Surges on Biotech Boom – Analysts Eye $650 Target

Thermo Fisher (TMO) Stock Surges on Biotech Boom – Analysts Eye $650 Target

Thermo Fisher (TMO) closed at $558.07 on Oct 21, up 2.6% for the day and over 11% in October, rebounding from a 10% year-over-year dip. The company has spent $2 billion on U.S. operations and announced a $4.1 billion deal for Solventum’s filtration business. Q3 results are due Oct 22, with analysts expecting EPS of ~$5.50 and revenue near $10.91 billion. JP Morgan raised its 12-month price target to $650.
21 October 2025
·
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Beyond the Eyepiece: The Next-Gen Microscopes of 2025–2026 Revolutionizing How We See the World

Beyond the Eyepiece: The Next-Gen Microscopes of 2025–2026 Revolutionizing How We See the World

Zeiss launched Lightfield 4D in March 2025, enabling instant volumetric imaging in LSM 910/990 microscopes at up to 80 stacks per second, with Microscopy Copilot AI. Nikon released the Eclipse Ti2-I in July 2025 for IVF clinics, consolidating controls and reducing workflow steps by up to 75%. Leica’s Visoria series debuted in May 2025 with tablet-based viewing and automatic metadata encoding.
31 July 2025
····
1 2 3 4

Stock Market Today

  • Tracker Funds Outperform Active Managers with Lower Costs, High Diversification
    June 29, 2026, 2:19 AM EDT. Tracker funds, also known as passive funds, have outperformed actively managed funds consistently over the past decade, according to AJ Bell's report. These funds mirror market indices like the FTSE 100 or S&P 500, offering diversification by investing across all companies in the index. Unlike active funds, which require fund managers to pick stocks, trackers reduce costs by eliminating management fees. Only 29% of active managers outperformed trackers in 2025. The approach, championed by Vanguard founder Jack Bogle, is summarized as "buy the haystack, not the needle." Trackers typically weight holdings by market capitalization, and come in structures such as exchange-traded funds (ETFs) or open-ended investment companies (OEICs), making them a favored choice for new and cost-conscious investors.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop